Potential of gene therapy for Parkinson's disease: Neurobiologic issues and new developments in gene transfer methodologies

Movement Disorders

Volumn 13, Issue SUPPL. 1, 1998, Pages 59-72

  Kang, Un Jung ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Aromatic L amino acid decarboxylase; Brain derived neurotrophic factor; Glial cell line derived neurotrophic factor; GTP cyclohydrolase 1; Lentivirus; Tyrosine hydroxylase

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CARBOXYLYASE; DOPAMINE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; APOPTOSIS; CONFERENCE PAPER; DOPAMINE METABOLISM; GENE THERAPY; GENE TRANSFER; NERVE CELL; NEURITE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

BRAIN-DERIVED NEUROTROPHIC FACTOR; DOPAMINE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; NERVE GROWTH FACTORS; NERVE REGENERATION; NERVE TISSUE PROTEINS; PARKINSON DISEASE; TYROSINE 3-MONOOXYGENASE;

EID: 0031945063     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (109)

1. Miller AD. Human gene therapy comes of age. Nature 1992;357: 455-460.
2. Mulligan RC. The basic science of gene therapy. Science 1993; 260:926-932.
3. Gage FH, Kawaja MD, Fisher LJ. Genetically modified cells: applications for intracerebral grafting. Trends Neurosci 1991;14: 328-333.
4. Kang UJ. Genetic modification of cells with retrovirus vectors for grafting into the central nervous system. In: Kaplitt MG, Loewy AD, eds. Viral vectors: Gene therapy and neuroscience applications. San Diego, CA: Academic Press, 1995:211-237.
5. Breakefield XO. Gene delivery into the brain using virus vectors. Nat Genet 1993;3:187-189.
6. Freese A, Stern M, Kaplitt MG, et al. Prospects for gene therapy in Parkinson's disease. Mov Disord 1996;5:469-488.
7. Raymon HK, Thode S, Gage FH. Application of ex vivo gene therapy in the treatment of Parkinson's disease. Exp Neurol 1997; 144:82-91.
8. Blomer U, Naldini L, Verma IM, Trono D, Gage FH. Applications of gene therapy to the CNS. Hum Mol Genet 1996;5:1397-1404.
9. Wivel NA, Walters L. Germ-line gene modification and disease prevention: some medical and ethical perspectives. Science 1993; 262:533-538.
10. Kawaja MD, Fagan AM, Firestein BL, Gage FH. Intracerebral grafting of cultured autologous skin fibroblasts into the rat striatum: an assessment of graft size and ultrastructure. J Comp Neurol 1991;307:695-706.
11. Bencsics C, Wachtel SR, Milstien S, Hatakeyama K, Becker JB, Kang UJ. Double transduction with GTP cyclohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis of L-dopa by primary fibroblasts. J Neurosci 1996;16:4449-4456.
12. La Gamma EF, Weisinger G, Lenn NJ, Strecker RE. Genetically modified primary astrocytes as cellular vehicles for gene therapy in the brain. Cell Transplant 1993;2:207-214.
13. Lundberg C, Horellou P, Mallet J, Björklund A. Generation of dopa-producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene: in vitro characterization and in vivo effects in the rat Parkinson model. Exp Neurol 1996;139: 39-53.
14. Ridoux V, Robert JJ, Zhang X, Perricaudet M, Mallet J, Le Gal La Salle G. The use of adenovirus vectors for intracerebral grafting of transfected nervous cells. Neuroreport 1994;5:801-804.
15. Renfranz PJ, Cunningham MG, McKay DG. Region-specific differentiation of the hippocampal stem cell line HiB5 upon implantation into the developing mammalian brain. Cell 1991;66:713-729.
16. Snyder EY, Deitcher DL, Walsh C, Arnold-Aldea S, Hartwieg EA, Cepko CL. Multipotent neural cell lines can engraft and participate in development of mouse cerebellum. Cell 1992;68: 33-51.
17. Hoshimaru M, Ray J, Sah DWY, Gage FH. Differentiation of the immortalized adult neuronal progenitor cell line HC2S2 into neurons by regulatable suppression of the v-myc oncogene. Proc Natl Acad Sci USA 1996;93:1518-1523.
18. Gage FH, Coates PW, Palmer TD, et al. Survival and differentiation of adult neuronal progenitor cells transplanted to the adult brain. Proc Natl Acad Sci USA 1995;92:11879-11883.
19. Palmer TD, Ray J, Gage FH. FGF-2-responsive neuronal progenitors reside in proliferative and quiescent regions of the adult rodent brain. Mol Cell Neurosci 1995;6:474-486.
20. Reynolds BA, Tetzlaff W, Weiss S. A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes. J Neurosci 1992;12:4565-4574.
21. Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992;255:1707-1710.
22. Lundberg C, Bjorklund A. Host regulation of glial markers in intrastriatal grafts of conditionally immortalized neural stem cell lines. Neuroreport 1996;7:847-852.
23. Anton R, Kordower JH, Maidment NT, et al. Neural-targeted gene therapy for rodent and primate hemiparkinsonism. Exp Neurol 1994;127:207-218.
24. Martínez-Serrano A, Lundberg C, Horellou P, et al. CNS-derived neural progenitor cells for gene transfer of nerve growth factor to the adult rat brain: complete rescue of axotomized cholinergic neurons after transplantation into the septum. J Neurosci 1995; 15:5668-5680.
25. Adams FS, La Rosa FG, Kumar S, et al. Characterization and transplantation of two neuronal cell lines with dopaminergic properties. Neurochem Res 1996;21:619-627.
26. Ahmed S, Reynolds BA, Weiss S. BDNF enhances the differentiation but not the survival of CNS stem cell-derived neuronal precursors. J Neurosci 1995;15:5765-5778.
27. Santa-Olalla J, Covarrubias L. Random catecholaminergic differentiation of mesencephalic neural precursors. Neuroreport 1995; 6:2394-2398.
28. Dobson AT, Margolis TP, Sedarati F, Stevens JG, Feldman LT. A latent, nonpathogenic HSV-1-derived vector stably expresses B-galactosidase in mouse neurons. Neuron 1990;5:353-360.
29. Johnson PA, Yoshida K, Gage FH, Friedmann T. Effects of gene transfer into cultured CNS neurons with a replication-defective herpes simplex virus type 1 vector. Brain Res Mol Brain Res 1992;12:95-102.
30. Spaete RR, Frenkel N. The herpes simplex virus amplicon: a new eukaryotic defective-virus cloning-amplifying vector. Cell 1982; 30:295-304.
31. Geller AI, Keyomarsi K, Bryan J, Pardee AB. An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology. Proc Natl Acad Sci USA 1990;87:8950-8954.
32. During MJ, Naegele JR, O'Malley KL, Geller AI. Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 1994;266:1399-1403.
33. Johnson PA, Miyanohara A, Levine F, Cahill T, Friedmann T. Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1. J Virol 1992;66:2952-2965.
34. Isacson O. Behavioral effects and gene delivery in a rat model of Parkinson's disease. Science 1995;269:856.
35. Neve RL. Adenovirus vectors enter the brain. Trends Neurosci 1993;16:251-253.
36. Le Gal La Salle G, Robert JJ, Berrard S, et al. An adenovirus vector for gene transfer into neurons and glia in the brain. Science 1993;259:988-990.
37. Davidson BL, Allen ED, Kozarsky KF, Wilson JM, Roessler BJ. A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nat Genet 1993;3:219-223.
38. Ghadge G, Roos RP, Kang UJ, et al. CNS gene delivery by retrograde transport of recombinant replication-defective adenoviruses. Gene Ther 1995;2:132-137.
39. Byrnes AP, MacLaren RE, Charlton HM. Immunological instability of persistent adenovirus vectors in the brain: peripheral exposure to vector leads to renewed inflammation, reduced gene expression, and demyelination. J Neurosci 1996;16:3045-3055.
40. Stratford-Perricaudet LD, Makeh I, Perricaudet M, Briand P. Widespread long-term gene transfer to mouse skeletal muscles and heart. J Clin Invest 1992;90:626-630.
41. Tripathy SK, Goldwasser E, Lu M-M, Barr E, Leiden JM. Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus. Proc Natl Acad Sci USA 1994;91:11557-11561.
42. Horellou P, Vigne E, Castel M-N, et al. Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease. Neuroreport 1994;6:49-53.
43. Choi-Lundberg DL, Lin Q, Chang Y-N, et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997;275:838-841.
44. McCown TJ, Xiao X, Li J, Breese GR, Samulski RJ. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res 1996;713:99-107.
45. Kaplitt MG, Leone P, Samulski RJ, et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 1994;8:148-154.
46. Miller AD, Miller DG, Garcia JV, Lynch CM. Use of retroviral vectors for gene transfer and expression. Methods Enzymol 1993; 217:581-599.
47. Kolberg R. Gene-transfer virus contaminant linked to monkeys' cancer. J NIH Res 1992;4:43-44.
48. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. BioTechniques 1989;7:980-989.
49. Danos O, Mulligan RC. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA 1988;85:6460-6464.
50. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol Hum Dis Ser 1990;10:4239-1242.
51. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996;272:263-267.
52. Wolff JA, Fisher LJ, Jinnah HA, et al. Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson's disease. Proc Natl Acad Sci USA 1989;86:9011-9014.
53. Lindvall O, Sawle G, Widner H, et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 1994;35:172-180.
54. Horellou P, Brundin P, Kalen P, Mallet J, Björklund A. In vivo release of dopa and dopamine from genetically engineered cells grafted to the denervated rat striatum. Neuron 1990;5:393-402.
55. Fisher LJ, Jinnah HA, Kale LC, Higgins GA, Gage FH. Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-dopa. Neuron 1991;6:371-380.
56. Jiao S, Gurevich V, Wolff JA. Long-term correction of rat model of Parkinson's disease by gene therapy. Nature 1993;362:450-453.
57. Barker R, Dunnett SB. Ibotenic acid lesions of the striatum reduce drug-induced rotation in the 6-hydroxydopamine-lesioned rat. Exp Brain Res 1994;101:365-374.
58. Curran EJ, Albin RL, Becker JB. Adrenal medulla grafts in the hemiparkinsonian rat: profile of behavioral recovery predicts restoration of the symmetry between the two striata in measures of pre- and postsynaptic dopamine function. Neuroscience 1993;13: 3864-3877.
59. Hefti F, Melamed E, Wurtman RJ. Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization. Brain Res 1980;195:123-137.
60. Hudson JL, Van Horne CG, Strömberg I, et al. Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res 1993;626:167-174.
61. Horellou P, Guibert B, Leviel V, Mallet J. Retroviral transfer of a human tyrosine hydroxylase cDNA in various cell lines: regulated release of dopamine in mouse anterior pituitary AtT-20 cells. Proc Natl Acad Sci USA 1989;86:7233-7237.
62. Geller AI, During MJ, Oh YJ, Freese A, O'Malley K. An HSV-1 vector expressing tyrosine hydroxylase causes production and release of L-dopa from cultured rat striatal cells. J Neurochem 1995;64:487-496.
63. Uchida K, Tsuzaki N, Nagatsu T, Kohsaka S. Tetrahydrobiopterin-dependent functional recovery in 6-hydroxydopamine-treated rats by intracerebral grafting of fibroblasts transfected with tyrosine hydroxylase cDNA. Dev Neurosci 1992;14:173-180.
64. Nagatsu T. Biopterin cofactor and monoamine-synthesizing monooxygenases. Neurochem Int 1983;5:27-38.
65. Ichinose H, Ohye T, Takahashi E, et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase 1 gene. Nat Genet 1994;8:236-242.
66. Leff SE, Snyder RO, Kaspar BK, et al. In vivo L-dopa production and long-term expression via intrastriatal recombinant AAV injections in a rat model of Parkinson's disease [Abstract]. The 6th International Neural Transplantation Meeting 1997;25.
67. Kang UJ, Fisher LJ, Joh TH, O'Malley KL, Gage FH. Regulation of dopamine production by genetically modified primary fibroblasts. J Neurosci 1993;13:5203-5211.
68. Abercrombie ED, Bonatz AE, Zigmond MJ. Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 1990;525:36-44.
69. Kang UJ, Park DH, Wessel T, Baker H, Joh TH. Dopa-decarboxylation in the striata of rats with unilateral substantia nigra lesions. Neurosci Lett 1992;147:53-57.
70. Melamed E, Hefti F, Pettibone DJ, Liebman J, Wurtman RJ. Aromatic L-amino acid decarboxylase in rat corpus striatum: implications for action of L-dopa in parkinsonism. Neurology 1981; 31:651-655.
71. Hefti F, Melamed E, Wurtman RJ. The site of dopamine formation in rat striatum after L-dopa administration. J Pharmacol Exp Ther 1981;217:189-197.
72. Li X-M, Juorio AV, Paterson IA, Walz W, Zhu M-Y, Boulton AA. Gene expression of aromatic L-amino acid decarboxylase in cultured rat glial cells. J Neurochem 1992;59:1172-1175.
73. Juorio AV, Li X-M, Walz W, Paterson IA. Decarboxylation of L-dopa by cultured mouse astrocytes. Brain Res 1993;626:306-309.
74. Melamed E, Hefti F, Liebman J, Schlosberg AJ, Wurtman RJ. Serotonergic neurons are not involved in action of L-dopa in Parkinson's disease. Nature 1980;283:772-774.
75. Tashiro T, Kaneko T, Sugimoto T, Nagatsu I, Kikuchi H, Mizuno N. Striatal neurons with aromatic L-amino acid decarboxylase-like immunoreactivity in the rat. Neurosci Lett 1989;100:29-34.
76. Mura A, Jackson D, Manley MS, Young SJ, Groves PM. Aromatic L-amino acid decarboxylase immunoreactive cells in the rat striatum: a possible site for the conversion of exogenous L-dopa to dopamine. Brain Res 1995;704:51-60.
77. Ng LKY, Chase TN, Colburn RW, Kopin IJ. L-dopa in parkinsonism: a possible mechanism of action. Neurology 1972;22:688-696.
78. Tison F, Normand E, Jaber M, Aubert I, Bloch B. Aromatic L-amino-acid decarboxylase (dopa decarboxylase) gene expression in dopaminergic and serotoninergic cells of the rat brainstem. Neurosci Lett 1991;127:203-206.
79. Arai R, Karasawa N, Nagatsu T, Nagatsu I. Exogenous L-5-hydroxytryptophan is decarboxylated in neurons of the substantia nigra pars compacta and locus coeruleus of the rat. Brain Res 1995;669:145-149.
80. Wightman RM, Zimmerman JB. Control of dopamine extracellular concentration in rat striatum by impulse flow and uptake. Brain Res Brain Res Rev 1990;15:135-144.
81. Van Horne C, Hoffer BJ, Stromberg I, Gerhardt A. Clearance and diffusion of locally applied dopamine in normal and 6-hydroxydopamine-treated rats by intracerebral grafting of fibroblasts transfected with tyrosine hydroxylase cDNA. Pharmacol Exp Ther 1992;2663:1285-1292.
82. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand 1971;82(suppl 2367):69-93.
83. Wachtel SR, Bencsics C, Kang UJ. The role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease. J Neurochem 1997;69:2055-2063.
84. Nagatsu T, Levitt M, Udenfriend S. Tyrosine hydroxylase: the initial step in norepinephrine synthesis. J Biol Chem 1964;239: 2910-2917.
85. Ribeiro P, Wang Y, Citron BA, Kaufman S. Regulation of recombinant rat tyrosine hydroxylase by dopamine. Proc Natl Acad Sci USA 1992;89:9593-9597.
86. Kang UJ, Fisher LJ, Kuczenski R, Jinnah HA, Job TH, Gage FH. Grafting genetically modified cells in a rat model of Parkinson's disease [Abstract]. Neurology 1993;43(suppl 2):A222.
87. Kaddis FG, Clarkson ED, Weber MJ, et al. Intrastriatal grafting of Cos cells stably expressing human aromatic L-amino acid decarboxylase: neurochemical effects. J Neurochem 1997;68:1520-1526.
88. Ribeiro P, Wang Y, Citron BA, Kaufman S. Deletion mutagenesis of rat PC12 tyrosine hydroxylase regulatory and catalytic domains. J Mol Neurosci 1993;4:125-139.
89. Harada K, Wu J, Haycock JW, Goldstein M. Regulation of L-dopa biosynthesis by site-specific phosphorylation of tyrosine hydroxylase in AtT-20 cells expressing wild-type and serine 40-substituted enzyme. J Neurochem 1996;67:629-635.
90. Levivier M, Przedborski S, Bencsics C, Kang UJ. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci 1995;15:7810-7820.
91. Snider WD. Functions of the neurotrophins during nervous system development: what the knockouts are teaching us. Cell 1994; 77:627-638.
92. Biffo S, Offenhäuser N, Carter BD, Barde Y-A. Selective binding and internalization by truncated receptors restrict the availability of BDNF during development. Development 1995;121:2461-2470.
93. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 1994;91:5104-5108.
94. Kawaja MD, Gage FH. Reactive astrocytes are substrates for the growth of adult CNS axons in the presence of elevated levels of nerve growth factor. Neuron 1991;7:1019-1030.
95. Kawaja MD, Rosenberg MB, Yoshida K, Gage FH. Somatic gene transfer of nerve growth factor promotes the survival of axotomized septal neurons and the regeneration of their axons in adult rats. J Neurosci 1992;12:2849-2864.
96. Linnik MD, Zahos P, Geschwind MD, Federoff HJ. Expression of bcl-2 from a defective herpes simplex virus-1 vector limits neuronal death in focal cerebral ischemia. Stroke 1995;26:1670-1674.
97. Przedborski S, Kostic V, Jackson-Lewis V, et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci 1992;12:1658-1667.
98. Nakao N, Frodl EM, Widner H, et al. Overexpressing Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson's disease. Nat Med 1995;1:226-231.
99. Jordan J, Ghadge GD, Prehn JHM, et al. Expression of human copper/zinc-superoxide dismutase inhibits the death of rat sympathetic neurons caused by withdrawal of nerve growth factor. Mol Pharmacol 1995;47:1095-1100.
100. Kessler DA, Siegel JP, Noguchi PD, Zoon KC, Feiden KL, Woodcock J. Regulation of somatic-cell therapy and gene therapy by the Food and Drug Administration. N Engl J Med 1993;329: 1169-1173.
101. Palmer TD, Rosman GJ, Osborne WRA, Miller AD. Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc Natl Acad Sci USA 1991;88:1330-1334.
102. Scharfmann R, Axelrod JH, Verma IM. Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. Proc Natl Acad Sci USA 1991;88:4626-4630.
103. Dai Y, Roman M, Naviaux RK, Verma IM. Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo. Proc Natl Acad Sci USA 1992; 89:10892-10895.
104. Roemer K, Johnson PA, Friedmann T. Activity of the simian virus 40 early promoter-enhancer in herpes simplex virus type 1 vectors is dependent on its position, the infected cell type, and the presence of Vmw175. J Virol 1991;65:6900-6912.
105. Wu DK, Cepko CL. The stability of endogenous tyrosine hydroxylase protein in PC-12 cells differs from that expressed in mouse fibroblasts by gene transfer. J Neurochem 1994;62:863-872.
106. No D, Yao TP, Evans RM. Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc Natl Acad Sci USA 1996;93:3346-3351.
107. Corti O, Horellou P, Colin P, Cattaneo E, Mallet J. Intracerebral tetracycline-dependent regulation of gene expression in grafts of neural precursors. Neuroreport 1996;7:1655-1659.
108. Dhawan J, Rando TA, Elson SL, Bujard H, Blau HM. Tetracycline-regulated gene expression following direct gene transfer into mouse skeletal muscle. Somat Cell Mol Genet 1995;21:233-240.
109. Lundberg C, Martinez-Serrano A, Cattaneo E, McKay RDG, Bjorklund A. Survival, integration and differentiation of neural stem cell lines after transplantation to the adult rate striatum. Exp Neurol 1996;145:342-360.